FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 315:1318-1327 November 20, 1986 Number 21 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We conducted a randomized, double-blind, placebo-controlled trial to test the efficacy of the 14-valent pneumococcal capsular polysaccharide vaccine in 2295 high-risk patients (patients with one or more of the following: age above 55 years and the presence of chronic cardiac, pulmonary, renal, or hepatic disease, alcoholism, or diabetes mellitus). Seventy-one episodes of proved or probable pneumococcal pneumonia or bronchitis occurred among 63 of the patients (27 placebo recipients and 36 vaccine recipients). Vaccine-serotype Streptococcus pneumoniae strains were recovered in association with 11 infections in the placebo group and 14 infections in the vaccine group. Pneumococcal infections occurred most frequently among patients with chronic pulmonary, cardiac, or renal diseases. Among vaccine recipients who subsequently had vaccine-type pneumonia or bronchitis, the majority did not make or sustain serum antibodies against their infecting organism in concentrations that were twice as high as the base-line values, or more than 400 ng of antibody nitrogen per milliliter, although their base-line levels were higher than those in subjects in whom infection did not develop. We were unable to demonstrate any efficacy of the pneumococcal vaccine in preventing pneumonia or bronchitis in this population. Our data suggest that chronically ill patients, who are most susceptible to infection, may have an impaired immune response to the pneumococcal vaccine.

This article has been cited by other articles:

• Schenkein, J. G., Nahm, M. H., Dransfield, M. T. (2008). Pneumococcal Vaccination for Patients With COPD: Current Practice and Future Directions. Chest 133: 767-774 [Abstract] [Full Text]  
• Chen, M., Hisatomi, Y., Furumoto, A., Kawakami, K., Masaki, H., Nagatake, T., Sueyasu, Y., Iwanaga, T., Aizawa, H., Oishi, K. (2007). Comparative Immune Responses of Patients with Chronic Pulmonary Diseases during the 2-Year Period after Pneumococcal Vaccination. CVI 14: 139-145 [Abstract] [Full Text]  
• Kapetanovic, M. C., Saxne, T., Sjoholm, A., Truedsson, L., Jonsson, G., Geborek, P. (2006). Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45: 106-111 [Abstract] [Full Text]  
• File, T. M. Jr, Tan, J. S. (2005). Pneumonia in Older Adults: Reversing the Trend. JAMA 294: 2760-2763 [Full Text]  
• Vila-Corcoles, A., Ochoa-Gondar, O., Llor, C., Hospital, I., Rodriguez, T., Gomez, A. (2005). Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. Eur Respir J 26: 1086-1091 [Abstract] [Full Text]  
• Smithson, S. L., Kolibab, K., Shriner, A. K., Srivastava, N., Khuder, S., Westerink, M. A. J. (2005). Immune Response to Pneumococcal Polysaccharides 4 and 14 in Elderly and Young Adults: Analysis of the Variable Light Chain Repertoire. Infect. Immun. 73: 7477-7484 [Abstract] [Full Text]  
• Hara, J., Stone, S. (2005). Antibiotics for Life-Threatening Illness. Journal of Pharmacy Practice 18: 336-350 [Abstract]  
• Mangtani, P., Roberts, J. A, Hall, A. J, Cutts, F. T (2005). An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Int J Epidemiol 34: 565-574 [Abstract] [Full Text]  
• Christenson, B., Hedlund, J., Lundbergh, P., Ortqvist, A. (2004). Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 23: 363-368 [Abstract] [Full Text]  
• Jackson, L. A., Neuzil, K. M., Yu, O., Benson, P., Barlow, W. E., Adams, A. L., Hanson, C. A., Mahoney, L. D., Shay, D. K., Thompson, W. W., the Vaccine Safety Datalink, (2003). Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults. NEJM 348: 1747-1755 [Abstract] [Full Text]  
• Artz, A. S., Ershler, W. B., Longo, D. L. (2003). Pneumococcal Vaccination and Revaccination of Older Adults. Clin. Microbiol. Rev. 16: 308-318 [Abstract] [Full Text]  
• MacNee, W, Calverley, P M A (2003). Chronic obstructive pulmonary disease * 7: Management of COPD. Thorax 58: 261-265 [Abstract] [Full Text]  
• Jonsson, S., Vidarsson, G., Valdimarsson, H., Schiffman, G., Schneerson, R., Jonsdottir, I. (2002). Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine. Eur Respir J 20: 813-818 [Abstract] [Full Text]  
• Pepper, P. V., Owens, D. K. (2002). Cost-Effectiveness of the Pneumococcal Vaccine in Healthy Younger Adults. Med Decis Making 22: S45-S57 [Abstract]  
• Ortqvist, A. (2001). Pneumococcal vaccination: current and future issues. Eur Respir J 18: 184-195 [Abstract] [Full Text]  
• Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., Martinez, F., Marrie, T. J., Plouffe, J. F., Ramirez, J., Sarosi, G. A., Torres, A., Wilson, R., Yu, V. L. (2001). Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am. J. Respir. Crit. Care Med. 163: 1730-1754 [Full Text]  
• Foster, D. A., Heller, S. T., Young, J. K., Tayloe, D., Wilbur, R. S., Whitney, C. G., Wenzel, R. P., Edmond, M. B. (2001). Multidrug-Resistant Streptococcus pneumoniae. NEJM 344: 1329-1331 [Full Text]  
• PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., HURD, S. S. (2001). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease . NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am. J. Respir. Crit. Care Med. 163: 1256-1276 [Full Text]  
• Carson, P. J., Nichol, K. L., O'Brien, J., Hilo, P., Janoff, E. N. (2000). Immune Function and Vaccine Responses in Healthy Advanced Elderly Patients. Arch Intern Med 160: 2017-2024 [Abstract] [Full Text]  
• Nichol, K. L., Baken, L., Wuorenma, J., Nelson, A. (1999). The Health and Economic Benefits Associated With Pneumococcal Vaccination of Elderly Persons With Chronic Lung Disease. Arch Intern Med 159: 2437-2442 [Abstract] [Full Text]  
• Rubins, J. B., Alter, M., Loch, J., Janoff, E. N. (1999). Determination of Antibody Responses of Elderly Adults to All 23 Capsular Polysaccharides after Pneumococcal Vaccination. Infect. Immun. 67: 5979-5984 [Abstract] [Full Text]  
• Nuorti, J. P., Butler, J. C., Crutcher, J. M., Guevara, R., Welch, D., Holder, P., Elliott, J. A. (1998). An Outbreak of Multidrug-Resistant Pneumococcal Pneumonia and Bacteremia among Unvaccinated Nursing Home Residents. NEJM 338: 1861-1868 [Abstract] [Full Text]  
• Musher, D. M. (1998). Pneumococcal Outbreaks in Nursing Homes. NEJM 338: 1915-1916 [Full Text]  
• Jain, A, Jain, S, Gant, V (1995). Should patients positive for HIV infection receive pneumococcal vaccine?. BMJ 310: 1060-1062 [Full Text]